|
|
|
|
|
Project Research HighlightsThe COBRE CCRD supports five investigators. Rachel Altura, MD, a pilot project investigator who recently joined the department of pediatrics, will examine the role that cetylation plays in the localization, dimerization and activity of surviving as a regulator of cell division and an inhibitor of apoptosis. For more information on Dr. Altura and her research, please visit her Brown Medical School profile. Devasis Chatterjee, PhD, a full project investigator who joined CCRD in year 5, will focus on raf kinase inhibitory protein (RKIP), a potential biomarker for susceptibility to chemotherapy and an inhibitor of STAT3 mediated metastasis of human colon cancer. For more information on Chaterjee and his research, please visit his Brown Medical School profile. Y. Eugene Chin, MD, PhD, the first CCRD full project investigator from the department of surgery, will examine the role of acetylation dependent STAT3 signaling pathways in self-renewal and metastasis of cancer stem cells isolated from human and hepatocellular carcinoma cell lines. For more information about Chin and his research, please visit his Brown Medical School profile. Steven Moss, MD, a former full project investigator recently awarded his first RO1, will remain with CCRD as a pilot project investigator and will continue to develop a new line of research centered on the role of gastrokine-1 and 2 in gastric cancer, two novel genes shown in his first cycle of COBRE funding to be altered following H. pylori eradication. For more information on Dr. Moss and his research, please visit his Brown Medical School profile. Dr. Sanders, a new full project investigator from Brown University, will investigate the mitogenic signaling phenotype of bipotent hepatic progenitors isolated from fetal and adult liver and how these pathways are influenced by the adult liver microenvironment. One Hoppin Street • Providence, RI 02903 |
|
|
|
